These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
389 related articles for article (PubMed ID: 19876745)
1. Prediction of solubility and permeability class membership: provisional BCS classification of the world's top oral drugs. Dahan A; Miller JM; Amidon GL AAPS J; 2009 Dec; 11(4):740-6. PubMed ID: 19876745 [TBL] [Abstract][Full Text] [Related]
2. The Biopharmaceutics Classification System: subclasses for in vivo predictive dissolution (IPD) methodology and IVIVC. Tsume Y; Mudie DM; Langguth P; Amidon GE; Amidon GL Eur J Pharm Sci; 2014 Jun; 57():152-63. PubMed ID: 24486482 [TBL] [Abstract][Full Text] [Related]
3. A provisional biopharmaceutical classification of the top 200 oral drug products in the United States, Great Britain, Spain, and Japan. Takagi T; Ramachandran C; Bermejo M; Yamashita S; Yu LX; Amidon GL Mol Pharm; 2006; 3(6):631-43. PubMed ID: 17140251 [TBL] [Abstract][Full Text] [Related]
4. Is the full potential of the biopharmaceutics classification system reached? Bergström CA; Andersson SB; Fagerberg JH; Ragnarsson G; Lindahl A Eur J Pharm Sci; 2014 Jun; 57():224-31. PubMed ID: 24075971 [TBL] [Abstract][Full Text] [Related]
5. Molecular properties of WHO essential drugs and provisional biopharmaceutical classification. Kasim NA; Whitehouse M; Ramachandran C; Bermejo M; Lennernäs H; Hussain AS; Junginger HE; Stavchansky SA; Midha KK; Shah VP; Amidon GL Mol Pharm; 2004 Jan; 1(1):85-96. PubMed ID: 15832504 [TBL] [Abstract][Full Text] [Related]
6. A comparative analysis of biopharmaceutics classification system and biopharmaceutics drug disposition classification system: a cross-sectional survey with 500 bioequivalence studies. Cristofoletti R; Chiann C; Dressman JB; Storpirtis S J Pharm Sci; 2013 Sep; 102(9):3136-44. PubMed ID: 23580377 [TBL] [Abstract][Full Text] [Related]
7. pH-Dependent solubility and permeability criteria for provisional biopharmaceutics classification (BCS and BDDCS) in early drug discovery. Varma MV; Gardner I; Steyn SJ; Nkansah P; Rotter CJ; Whitney-Pickett C; Zhang H; Di L; Cram M; Fenner KS; El-Kattan AF Mol Pharm; 2012 May; 9(5):1199-212. PubMed ID: 22489626 [TBL] [Abstract][Full Text] [Related]
8. Provisional classification and in silico study of biopharmaceutical system based on caco-2 cell permeability and dose number. Pham-The H; Garrigues T; Bermejo M; González-Álvarez I; Monteagudo MC; Cabrera-Pérez MÁ Mol Pharm; 2013 Jun; 10(6):2445-61. PubMed ID: 23675957 [TBL] [Abstract][Full Text] [Related]
9. Classification of orally administered drugs on the World Health Organization Model list of Essential Medicines according to the biopharmaceutics classification system. Lindenberg M; Kopp S; Dressman JB Eur J Pharm Biopharm; 2004 Sep; 58(2):265-78. PubMed ID: 15296954 [TBL] [Abstract][Full Text] [Related]
10. The biowaiver extension for BCS class III drugs: the effect of dissolution rate on the bioequivalence of BCS class III immediate-release drugs predicted by computer simulation. Tsume Y; Amidon GL Mol Pharm; 2010 Aug; 7(4):1235-43. PubMed ID: 20557130 [TBL] [Abstract][Full Text] [Related]
11. The use of biopharmaceutic classification of drugs in drug discovery and development: current status and future extension. Lennernäs H; Abrahamsson B J Pharm Pharmacol; 2005 Mar; 57(3):273-85. PubMed ID: 15807982 [TBL] [Abstract][Full Text] [Related]
12. Feasibility of biowaiver extension to biopharmaceutics classification system class III drug products: cimetidine. Jantratid E; Prakongpan S; Amidon GL; Dressman JB Clin Pharmacokinet; 2006; 45(4):385-99. PubMed ID: 16584285 [TBL] [Abstract][Full Text] [Related]
13. Comparing multilabel classification methods for provisional biopharmaceutics class prediction. Newby D; Freitas AA; Ghafourian T Mol Pharm; 2015 Jan; 12(1):87-102. PubMed ID: 25397721 [TBL] [Abstract][Full Text] [Related]
14. Impact of the US FDA "Biopharmaceutics Classification System" (BCS) Guidance on Global Drug Development. Mehta MU; Uppoor RS; Conner DP; Seo P; Vaidyanathan J; Volpe DA; Stier E; Chilukuri D; Dorantes A; Ghosh T; Mandula H; Raines K; Dhanormchitphong P; Woodcock J; Yu LX Mol Pharm; 2017 Dec; 14(12):4334-4338. PubMed ID: 29076742 [TBL] [Abstract][Full Text] [Related]
15. In silico predictions of gastrointestinal drug absorption in pharmaceutical product development: application of the mechanistic absorption model GI-Sim. Sjögren E; Westergren J; Grant I; Hanisch G; Lindfors L; Lennernäs H; Abrahamsson B; Tannergren C Eur J Pharm Sci; 2013 Jul; 49(4):679-98. PubMed ID: 23727464 [TBL] [Abstract][Full Text] [Related]
16. Predicting drug disposition via application of BCS: transport/absorption/ elimination interplay and development of a biopharmaceutics drug disposition classification system. Wu CY; Benet LZ Pharm Res; 2005 Jan; 22(1):11-23. PubMed ID: 15771225 [TBL] [Abstract][Full Text] [Related]
17. Evaluation and suggested improvements of the Biopharmaceutics Classification System (BCS). Fagerholm U J Pharm Pharmacol; 2007 Jun; 59(6):751-7. PubMed ID: 17637167 [TBL] [Abstract][Full Text] [Related]
18. Very rapid dissolution is not needed to guarantee bioequivalence for biopharmaceutics classification system (BCS) I drugs. Kortejärvi H; Shawahna R; Koski A; Malkki J; Ojala K; Yliperttula M J Pharm Sci; 2010 Feb; 99(2):621-5. PubMed ID: 19844950 [TBL] [Abstract][Full Text] [Related]
19. Integrating theoretical and experimental permeability estimations for provisional biopharmaceutical classification: Application to the WHO essential medicines. Cabrera-Pérez MÁ; Pham-The H; Cervera MF; Hernández-Armengol R; Miranda-Pérez de Alejo C; Brito-Ferrer Y Biopharm Drug Dispos; 2018 Jul; 39(7):354-368. PubMed ID: 30021059 [TBL] [Abstract][Full Text] [Related]